Lenalidomide for the treatment of relapsed and refractory multiple myeloma. - Wikidata - wikimedia - TriplyDB

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

http://www.wikidata.org/entity/Q33403183

about

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma.Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation.Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

P2860

Q26766718-C7A79ED1-E4A8-4704-B8DF-1E68B0D53DA7 Q34543937-D068170C-BA64-4C56-9A47-D7C92C3F2192 Q35669893-4D032FE7-83EE-4277-909F-D751E15E5528 Q39341524-00401AE4-3EF3-40C3-A3C6-E1DDE55942F3 Q40527891-B41BAD77-09F1-410C-8D7D-03FBCF75FD44 Q43979784-FEA7893C-0B46-422F-84C4-D5E7D7960BA3 Q52801394-A4387FCF-CAD6-45D1-900E-FF5EAE60AFB4 Q58552961-095F2D27-0A4D-4B45-BEA2-829DFEBA6B2B

P2860

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

http://www.wikidata.org/entity/Q33403183

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

@ast

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

@en

type

label

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

@ast

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

@en

prefLabel

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

@ast

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

@en

P1433

Q33403183-29851C54-40E1-4E17-8436-B94CD79C5F3F

P1476

Q33403183-BF98D2E7-0889-4529-9C8D-BD87E2E5F6A5

P2093

Q33403183-29E57073-DF1F-4251-971F-687ECE34DBC2

Q33403183-3BF72275-BB92-45EC-9115-E963FA3370C2

Q33403183-92F30B67-B786-4A4D-8DED-87C6E36919C5

Q33403183-9406A1CB-1519-4AC7-9ACF-6F24B647D015

Q33403183-B7B70196-2D68-4701-9972-C2ACC22FAF25

Q33403183-B9778D0D-4955-479F-87E8-A0651950986E

Q33403183-CA81C812-CAC1-4295-9345-DA72A225DB5A

Q33403183-E21ED6C3-B3BB-410A-83DC-1CCE5A43514B

Q33403183-E7405F28-8572-4665-98D8-075F1973B96E

Q33403183-F524B590-50D1-44BB-80DE-B8700D97CF08

P2860

Q33403183-00748571-1AC6-46E8-A465-53D2E782090D

Q33403183-007E9DD0-528F-4005-8B5D-E27F16AFA8B8

Q33403183-00DA195D-8F24-4C3E-9D72-4003508C0D54

Q33403183-03754B97-161F-4215-ABD3-D82315ADE21B

Q33403183-0B50EC90-4800-4510-A7E3-95811EB94268

Q33403183-1528E64F-10BC-49D0-8CB8-5993D564694F

Q33403183-195014FC-73F9-4536-AEC4-93ED87ACC21C

Q33403183-1A062F94-DC6F-485E-BEA3-BBF1D9399B03

Q33403183-1C2FB07C-037A-4142-BBDC-614414115E26

Q33403183-1DB760BC-0531-4475-9804-19194168FF75

P304

Q33403183-56B67F67-99D4-4444-ACAA-4C9BDC5D8EC1

P31

Q33403183-16F42CB6-57EE-4621-AB0E-D7D52340BCA3

P356

Q33403183-B57FAA8B-05AA-45B8-BCC3-594326D4355F

P407

Q33403183-498C910C-C3E9-449B-AFEE-165A4A8040F5

P478

Q33403183-4873AFFA-3EF6-44BF-8FB0-9344C3939EF4

P50

Q33403183-76EACB0C-FE1A-4F1A-AE98-F5A4A9212660

Q33403183-81B82873-D882-400A-8213-9A67CE13038E

P577

Q33403183-816FEB29-0814-4662-B908-1113638C52F0

P698

Q33403183-E6180B99-33F5-49BE-BACD-3ACB975A5ECA

P932

Q33403183-B27E0DC6-C8CA-43A7-A402-C9CD4274982F

P356

P1433

Cancer Management and Research

P1476

Lenalidomide for the treatment of relapsed and refractory multiple myeloma

@en

P2093

Constantine S Mitsiades

http://www.w3.org/2001/XMLSchema#string

Güllü Görgün

http://www.w3.org/2001/XMLSchema#string

Henk M Lokhorst

http://www.w3.org/2001/XMLSchema#string

Inger S Nijhof

http://www.w3.org/2001/XMLSchema#string

Jacob Laubach

http://www.w3.org/2001/XMLSchema#string

Jana Jakubikova

http://www.w3.org/2001/XMLSchema#string

Niels Wcj van de Donk

http://www.w3.org/2001/XMLSchema#string

Paul G Richardson

http://www.w3.org/2001/XMLSchema#string

Reinier A Raymakers

http://www.w3.org/2001/XMLSchema#string

Teru Hideshima

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of lenalidomide in hematological malignancies

Identification of a primary target of thalidomide teratogenicity

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

P304

253-268

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S27087

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Richard W Groen

Kenneth C Anderson

P577

2012-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22956884

http://www.w3.org/2001/XMLSchema#string

P932

3430086

http://www.w3.org/2001/XMLSchema#string